leisure time -WSS

leisure time

author：explore 2025-09-30 18:59:07 - browse：9165

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Guardant Health colon cancer test endorsed by FDA advisory panel

WSS

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Achieving telehealth equity for people with hearing loss

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Unmasking the 'centricity' illusion in clinical trials

Male and female sex labels in research insufficient, scientists say

Louisiana bill approved classifying abortion pills as controlled substances

entertainment

leisure time

focus

Apple is now the first public company to be valued at $3 trillion

WuXi out of biotech trade group, U.S. and China relations to blame

FDA approval of Sarepta Duchenne genetic therapy gives me hope

President Biden's budget: Here's what you might have missed

In Memoriam: Notable people who died in 2023

J&J reports mixed data on next

Supreme Court strikes down use of affirmative action

As AI in medicine takes off, can 'human in the loop' prevent harm?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

focus

Change Healthcare outage fallout shows need for new oversight

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Some medical students still think black patients feel less pain

Amid AI frenzy, a top HHS official's quest to create safeguards

entertainment

leisure time

hotspot

knowledge